Tsingke Biotech Integrates AI Tools with Nucleic Acid Synthesis
Tsingke Biotech has expanded its operations in Beijing to combine artificial intelligence with automated manufacturing for nucleic acid and gene synthesis.
Tsingke Biotech is scaling its operations by linking AI-driven molecular design with physical production infrastructure. The initiative aims to synchronize computational design platforms with high-throughput laboratory automation to accelerate the gene synthesis process.
By incorporating automated manufacturing, the company seeks to reduce the turnaround time between digital molecular modeling and experimental validation. This shift reflects a broader trend within the biotechnology sector to minimize human intervention in the synthesis workflow.
Tsingke plans to utilize this integrated approach to support pharmaceutical and academic research projects that require rapid sequence verification and large-scale genetic material production. The strategy represents an attempt to bridge the gap between predictive modeling and tangible laboratory results.